Protevasc SR

  • Active substance

    Trimetazidini dihydrochloridum

  • Dosage

    35 mg

  • Therapeutic area
  • Pharmaceutical form

    Prolonged release tablets

  • Product category


  • Refund


Brochure Protevasc SR

  • Driving a car


  • Taking on an empty stomach


  • Breast feeding


  • Drug storage

    Przechowywać w opakowaniu w celu ochrony przed wilgocią, w temp. poniżej 25 °C

Download brochure PDF Download


According to the World Health Organisation, heart and circulatory diseases are the most common causes of deaths in developed countries, while arterial hypertension – which is an extremely dangerous and chronic disease – is the most common condition affecting the circulatory system.

See more products from Cardiology

Worth to read

Identity confirmation

This section contains information intended solely for doctors, pharmacists and other persons authorised to receive specialty medical information.

If you are a doctor, pharmacist or are otherwise authorised to receive specialty medical information continue to the next page.

  • Doctors
  • Pharmacists
  • Medical

W przeciwnym razie, zapraszamy do zapoznania się z pozostałą częścią naszego serwisu powrót do strony głównej

Back to patient information

How are drugs manufactured

From idea to patient

We are all looking forward to new, excellent medicines and even more effective therapies. Sometimes, it takes a long time before the drug will be released to the market. It usually starts with the idea of ​​a new product, a long period of research, testing, and the production and distribution of the new medicine.

Read more